newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical st